Pfizer is suing Metsera and Novo Nordisk over Novo's $9 billion bid to acquire Metsera, arguing significant regulatory risk ...

The top seven customers of the hard-drive company have provided purchase orders through at least the first half of next year. The company said it is on track to meet its advisor retention goals for ...

Pfizer is suing over some unsolicited competition in its nearly $5 billion bid to buy the drugmaker Metsera. New York-based Pfizer said Friday after markets closed that it was suing Metsera and a ...

Pfizer Inc. sued Metsera Inc. and rival drugmaker Novo Nordisk A/S to block the Danish company’s rival bid for the obesity ...

Shares of Novo Nordisk, the Danish maker of Ozempic and Wegovy, which had long led the weight-control drug sales, fell after analysts at brokerage Deutsche Bank said a $9 billion attempt to wrest ...

Pfizer has filed a lawsuit against Metsera and Novo Nordisk, claiming Metsera violated its merger agreement by entertaining ...

Pfizer has received early U.S. antitrust clearance more than a week early for its proposed $7.3 billion Metsera acquisition, ...

Pfizer said on Friday it has received an early clearance from the U.S. Federal Trade Commission for its proposed acquisition ...

U.S. drugmaker Pfizer could work its connections within President Donald Trump's administration to try to thwart Novo Nordisk ...

President Donald Trump has received updated flu and COVID-19 booster shots in preparation for upcoming travel, the president’s physician announced Oct. 10. Sean P. Barbabella, a U.S. Navy captain, ...

The Global Anti-Obesity Drug Market is estimated to be valued at USD 25.87 Bn in 2025 and is expected to reach USD 82.55 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 18.01% from 2025 ...